Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 18/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223237 | 1.00 | SIGMAR1 (0.55) | SIGMAR1HTR1AADRA2ADRD2ADRA2C | |
| SCHEMBL634119 | 0.84 | SIGMAR1 (0.55) | SIGMAR1GRK2KMT2ACTDSP1 | |
| SCHEMBL633011 | 0.84 | SIGMAR1 (0.52) | SIGMAR1HTR1AADRA2ADRD2ADRA2C | |
| SCHEMBL633009 | 0.84 | SIGMAR1 (0.52) | SIGMAR1HTR1AADRA2ADRD2ADRA2C | |
| SCHEMBL591159 | 0.82 | MAOA (0.59) | SIGMAR1GRK2KMT2ACTDSP1 | |
| SCHEMBL591161 | 0.82 | MAOA (0.59) | SIGMAR1GRK2KMT2ACTDSP1 | |
| SCHEMBL591514 | 0.82 | MAOA (0.59) | SIGMAR1GRK2KMT2ACTDSP1 | |
| SCHEMBL1224794 | 0.80 | SIGMAR1 (0.49) | SIGMAR1GRK2KMT2ACTDSP1 | |
| SCHEMBL590026 | 0.79 | F10 (0.56) | SIGMAR1GRK2KMT2ACTDSP1 | |
| SCHEMBL632626 | 0.79 | KMT2A (0.48) | SIGMAR1GRK2KMT2ACTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2905283-B1 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2016-12-14 | — | — | EP | disclosed |
| EP-2915813-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-09-09 | — | — | EP | disclosed |
| EP-2905283-A1 | Oxazolidinone antibiotics | Actelion Pharmaceuticals Ltd. (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-8217029-B2 | Oxazolidinone antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039823-A1 | OXAZOLIDINONE ANTIBIOTICS | OXA1L, XDH, UBE2D3 | SIGMAR1 364/4885HTR1A 4255/4885ADRA2A 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.